Cereno Scientific reports 1/3 of patients recruited into CS1 Phase II study in rare disease Pulmonary Arterial Hypertension (PAH)
Cereno Scientific (XSAT: CRNO B) today announced significant progress in the recruitment of patients into the study in the rare disease PAH with its lead candidate drug CS1. Now, a total of 10 patients have been enrolled into the study which plans to study 30 patients.We are now pleased to announce significant progress in the number of patients having had successful screening visits that are the first visit for a patient in the study. After all centers being activated in February and the new amendment being in place a high activity of active pre-screening started in all centers and a